Table 1.
Registered clinical trials of CRISPR/Cas9-engineered CAR-T cells for cancer therapy.
| NCT Number |
Phase | Target Gene | CAR-T Cell | Cancer | Location | Status |
|---|---|---|---|---|---|---|
| NCT03545815 | I | TRAC and PDCD1 | Mesothelin- CART | Mesothelin-positive multiple solid tumors | China | Completed |
| NCT04557436 | I | TRAC and CD52 | CD19-CART | Refractory B-cell leukemia |
The United Kingdom | Active; not recruiting |
| NCT03166878 | I/II | B2M | CD19-CART | B-cell leukemia | China | Recruiting |
| NCT04244656 | I | TCR and MHC class I | BCMA-CART | Multiple myeloma | The United States | Active, Not Recruiting |
| NCT04438083 | I | TRAC, B2M and CD70 | CD70-CART | Relapsed or refractory renal cell carcinoma | The United States | Active; not recruiting |
| NCT05643742 | I/II | TRAC and B2M | CD19-CART | Relapsed or refractory B-cell malignancies | The United States | Recruiting |
| NCT03747965 | I | PDCD1 | Mesothelin-CART | Mesothelin-positive multiple solid tumors | China | Completed |
| NCT04035434 | I | TRAC and B2M | CD19-CART | Relapsed or refractory B-cell malignancies | The United States | Recruiting |
| NCT03166878 | I/II | TRAC and B2M | CD19-CART | Relapsed or refractory CD19+ leukemia and lymphoma | China | Completed |
| NCT03398967 | I/II | TRAC and CD52 | CD19/20- or CD19/22-UCART |
Relapsed or refractory hematological malignancies | China | Unknown |
| NCT04976218 | I | TGF-β receptor II | EGFR-CART | Advanced EGFR-positive solid tumors | China | Recruiting |
| NCT05812326 | I/II | PDCD1 | MUC1-CART | MUC1-positive advanced breast cancer | China | Completed |
| NCT04037566 | I | HPK1 | CD19-CART | Hematopoietic malignancies |
China | Recruiting |
| NCT03203369 | I | TCR | CD123-CART | Blastic plasmacytoid dendritic cell neoplasm |
The United States | Discontinued |
| NCT04637763 | I | Unknown | CD19-CART | Relapsed/refractory B-cell non-Hodgkin lymphoma | The United States | Recruiting |
Data extracted from https://clinicaltrials.gov/ (last accessed 1 June 2023).